Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Xlife Sciences Ltd. ( (CH:XLS) ) just unveiled an update.
Xlife Sciences AG held a successful general meeting where all board proposals were approved, representing a significant shareholder trust. The company highlighted its progress in 2024, including the commercialization of AI-supported diagnostic solutions and the development of VERAXA Biotech towards a NASDAQ listing. Looking ahead, Xlife Sciences plans to expand internationally with a new US branch to enhance partnerships and project development. The inclusion of Firstgene Life Sciences GmbH into its portfolio marks a strategic expansion into precise gene therapies for liver cancer.
More about Xlife Sciences Ltd.
Xlife Sciences AG is a Swiss company that operates as an incubator and accelerator, focusing on the development and commercialization of promising research projects in the life sciences sector. The company aims to bridge the gap between research and healthcare markets by selecting projects in technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health to advance them to the next stage of development.
Average Trading Volume: 3,512
Current Market Cap: CHF112.8M
For a thorough assessment of XLS stock, go to TipRanks’ Stock Analysis page.